Clinical trial
A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD
NCT02543229 is registered in ClinicalTrials.gov with Opthea Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD
- Lead sponsor
- Opthea Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2015
- Completion date
- September 30, 2017
- Enrollment
- 51 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.